Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma

The modest clinical benefits of neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) are associated with a lack of robust data on treatment‐induced changes in the tumor. To this end, comparative proteomic profiling of tumor tissue samples from treatment‐naïve (TN, n = 20) and NA...

Descripción completa

Detalles Bibliográficos
Autores principales: Amrutkar, Manoj, Verbeke, Caroline S., Finstadsveen, Anette Vefferstad, Dorg, Linda, Labori, Knut Jørgen, Gladhaug, Ivar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812839/
https://www.ncbi.nlm.nih.gov/pubmed/36400567
http://dx.doi.org/10.1002/1878-0261.13344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812839/
https://www.ncbi.nlm.nih.gov/pubmed/36400567
http://dx.doi.org/10.1002/1878-0261.13344

Ejemplares similares